


PHARMACEUTICAL 2022

Mallinckrodt plc Rank 169 of 475







PHARMACEUTICAL 2022

Mallinckrodt plc Rank 169 of 475



The relative strengths and weaknesses of Mallinckrodt plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Mallinckrodt plc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 141% points. The greatest weakness of Mallinckrodt plc is the variable Other Liabilities, reducing the Economic Capital Ratio by 96% points.

The company's Economic Capital Ratio, given in the ranking table, is -29%, being 247% points above the market average of -276%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 2,309,600 |
| Cost of Goods Sold | 1,317,100 |
| Intangible Assets | 5,448,400 |
| Liabilities, Current | 1,942,200 |
| Liabilities, Non-Current | 85,800 |
| Other Assets | 382,300 |
| Other Compr. Net Income | 1,300 |
| Other Expenses | 851,300 |
| Other Liabilities | 6,574,900 |
| Other Net Income | 29,200 |
| Property and Equipment | 776,000 |
| Research and Development | 205,200 |
| Revenues | 2,208,800 |
| Selling, General and Administrative Expense | 581,800 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 8,916,300 |
| Liabilities | 8,602,900 |
| Expenses | 2,955,400 |
| Stockholders Equity | 313,400 |
| Net Income | -717,400 |
| Comprehensive Net Income | -716,750 |
| Economic Capital Ratio | -29% |